Conway Capital Management Inc. Makes New $954,000 Investment in Edwards Lifesciences Corporation $EW

Conway Capital Management Inc. purchased a new position in shares of Edwards Lifesciences Corporation (NYSE:EW) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 10,550 shares of the medical research company’s stock, valued at approximately $954,000. Edwards Lifesciences makes up about 0.4% of Conway Capital Management Inc.’s portfolio, making the stock its 27th biggest holding.

Other institutional investors also recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. boosted its position in Edwards Lifesciences by 27.3% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 109,749 shares of the medical research company’s stock valued at $9,356,000 after buying an additional 23,514 shares during the period. Norges Bank purchased a new stake in shares of Edwards Lifesciences during the fourth quarter valued at $803,686,000. TD Asset Management Inc raised its holdings in shares of Edwards Lifesciences by 6.4% during the fourth quarter. TD Asset Management Inc now owns 778,129 shares of the medical research company’s stock valued at $66,335,000 after purchasing an additional 47,051 shares during the last quarter. Intech Investment Management LLC lifted its holdings in shares of Edwards Lifesciences by 22.2% during the 4th quarter. Intech Investment Management LLC now owns 69,347 shares of the medical research company’s stock valued at $5,912,000 after buying an additional 12,591 shares during the period. Finally, Fideuram Intesa Sanpaolo Private Banking S.P.A. purchased a new position in Edwards Lifesciences in the fourth quarter worth about $1,626,000. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 619 shares of Edwards Lifesciences stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total value of $56,966.57. Following the completion of the sale, the vice president owned 40,034 shares in the company, valued at approximately $3,684,329.02. This trade represents a 1.52% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of the stock in a transaction dated Wednesday, May 27th. The stock was sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the sale, the vice president directly owned 98,611 shares in the company, valued at $8,521,962.62. This represents a 19.01% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 25,570 shares of company stock worth $2,219,390 over the last three months. Insiders own 0.31% of the company’s stock.

Edwards Lifesciences Stock Down 0.8%

Edwards Lifesciences stock opened at $90.84 on Tuesday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.52 and a quick ratio of 3.77. Edwards Lifesciences Corporation has a 12 month low of $72.30 and a 12 month high of $96.29. The stock has a market capitalization of $52.31 billion, a PE ratio of 52.21, a price-to-earnings-growth ratio of 2.30 and a beta of 0.85. The business has a 50 day simple moving average of $88.83 and a 200-day simple moving average of $84.43.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The business had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.70 billion. During the same quarter last year, the business posted $0.67 earnings per share. The business’s quarterly revenue was up 13.6% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, analysts anticipate that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently weighed in on EW shares. Truist Financial lifted their target price on Edwards Lifesciences from $90.00 to $95.00 and gave the company a “hold” rating in a research report on Thursday, July 16th. Piper Sandler reaffirmed an “overweight” rating and issued a $101.00 price objective (up from $100.00) on shares of Edwards Lifesciences in a research note on Friday, July 24th. Barclays restated an “overweight” rating and set a $110.00 target price (up from $104.00) on shares of Edwards Lifesciences in a research report on Monday, April 27th. Canaccord Genuity Group set a $85.00 target price on Edwards Lifesciences and gave the company a “hold” rating in a research report on Friday, April 24th. Finally, BTIG Research upped their target price on Edwards Lifesciences from $100.00 to $110.00 and gave the stock a “buy” rating in a report on Tuesday, June 30th. Seventeen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Edwards Lifesciences currently has an average rating of “Moderate Buy” and a consensus price target of $100.27.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.